Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 18, 2024

SELL
$1.75 - $3.44 $12,183 - $23,949
-6,962 Reduced 1.98%
344,060 $1.14 Million
Q4 2023

Jan 25, 2024

BUY
$1.74 - $2.31 $5,376 - $7,137
3,090 Added 0.89%
351,022 $740,000
Q3 2023

Oct 27, 2023

BUY
$2.11 - $3.28 $734,136 - $1.14 Million
347,932 New
347,932 $737,000
Q2 2023

Jul 18, 2023

SELL
$1.97 - $3.69 $37,132 - $69,552
-18,849 Reduced 6.21%
284,659 $913,000
Q1 2023

Apr 13, 2023

BUY
$2.14 - $3.4 $531,582 - $844,570
248,403 Added 450.78%
303,508 $658,000
Q4 2022

Jan 23, 2023

BUY
$2.03 - $2.42 $34,420 - $41,033
16,956 Added 44.45%
55,105 $0
Q3 2022

Oct 26, 2022

BUY
$1.67 - $2.94 $63,708 - $112,158
38,149 New
38,149 $89,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.63B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.